HN2000000225A - PHARMACEUTICALLY ACTIVE COMPOUNDS - Google Patents

PHARMACEUTICALLY ACTIVE COMPOUNDS

Info

Publication number
HN2000000225A
HN2000000225A HN2000000225A HN2000000225A HN2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A
Authority
HN
Honduras
Prior art keywords
active compounds
pharmaceutically active
pharmaceutically
veterinarily acceptable
compounds
Prior art date
Application number
HN2000000225A
Other languages
Spanish (es)
Inventor
Bunnage Mark Edward
Vries Keith Michael De
Harris Laurence James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2000000225A publication Critical patent/HN2000000225A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de fórmula (I): en la que R1, R2, R4 y R13 son como se definen o una sal farmacéutica o veterinariamente aceptable o polimorfo del mismo, o un solvato farmacéutica o veterinariamente aceptable o profármaco del mismo: son inhibidores potentes y selectivos de TIPO 5 CYCLIC GUANOSINE 3'', 5''-monofosfato fosfodiesterasa (cGMP PDE5) y tienen utilidad en el tratamiento de, entre otros, la disfunción eréctil masculina (MED) y la disfunción sexual femenina (DSF).The compounds of formula (I): wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable or polymorphic salt thereof, or a pharmaceutically or veterinarily acceptable solvate or prodrug thereof: they are potent inhibitors and selective TYPE 5 CYCLIC GUANOSINE 3 '', 5 '' - monophosphate phosphodiesterase (cGMP PDE5) and are useful in the treatment of, among others, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

HN2000000225A 1999-10-11 2000-10-05 PHARMACEUTICALLY ACTIVE COMPOUNDS HN2000000225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924063.2A GB9924063D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
HN2000000225A true HN2000000225A (en) 2001-04-16

Family

ID=10862547

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2000000225A HN2000000225A (en) 1999-10-11 2000-10-05 PHARMACEUTICALLY ACTIVE COMPOUNDS

Country Status (4)

Country Link
GB (1) GB9924063D0 (en)
HN (1) HN2000000225A (en)
UA (1) UA72773C2 (en)
ZA (1) ZA200202763B (en)

Also Published As

Publication number Publication date
UA72773C2 (en) 2005-04-15
GB9924063D0 (en) 1999-12-15
ZA200202763B (en) 2003-06-25

Similar Documents

Publication Publication Date Title
CU23198A3 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
TR200003039T2 (en) Pirazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunctions
PE20040197A1 (en) PYRAZOLOPYRIDINES SUBSTITUTED WITH CARBAMATE
NO20015275D0 (en) Unit dosage form
HN2000000225A (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
ECSP003703A (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
UY26387A1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
PA8523501A1 (en) CRYSTAL THERAPEUTIC AGENT
MY131573A (en) Use of pde5 inhibitors for the treatment of premature ejaculation
AR030681A1 (en) PIRAZOLO COMPOUNDS [4,3-] PIRIMIDIN-7-ONAS, PHARMACEUTICAL COMPOSITION, VETERINARY FORMULATION, USE IN THE MANUFACTURE OF MEDICINAL PRODUCT, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, INTERMEDIARY COMPOUNDS AND THEIR PREPARATION
IL165411A0 (en) Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction